XDH and hyperuricemia: Although a series of promising alternative treatments of hyperuricemia including the utilization of interleukin-1 inhibitors, recombinant uricase therapy, or the targeting of renal urate transporters have been respectively investigated [8,9,10], XO inhibitors remain a primary therapy owing to the fundamental inhibition of uric acid production.